Literature DB >> 12360282

VEGF and the quest for tumour angiogenesis factors.

Napoleone Ferrara1.   

Abstract

The ability of tumours to induce new blood-vessel formation has been a major focus of cancer research over the past few decades, and vascular endothelial growth factor (VEGF) is now known to be central to this process. The quest for VEGF and other factors that promote tumour angiogenesis was initiated many decades ago, and a long and complicated path has led to the development of inhibitors of these molecules as anticancer agents. How did this field begin, and how have we arrived at our present understanding of the role of VEGF in tumour progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12360282     DOI: 10.1038/nrc909

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  408 in total

1.  Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

Authors:  Weijing Sun; Mark Powell; Peter J O'Dwyer; Paul Catalano; Rafat H Ansari; Al B Benson
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  Immunomodulatory glc/man-directed Dolichos lablab lectin (DLL) evokes anti-tumour response in vivo by counteracting angiogenic gene expressions.

Authors:  V Vigneshwaran; P Thirusangu; B R Vijay Avin; V Krishna; S N Pramod; B T Prabhakar
Journal:  Clin Exp Immunol       Date:  2017-04-05       Impact factor: 4.330

3.  Rho activity critically and selectively regulates endothelial cell organization during angiogenesis.

Authors:  Mien V Hoang; Mary C Whelan; Donald R Senger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

4.  Synthesis of ribozyme against vascular endothelial growth factor165 and its biological activity in vitro.

Authors:  Zhong-Ping Gu; Yun-Jie Wang; Yu Wu; Jin-Ge Li; Nong-An Chen
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

Review 5.  Protein-based tumor molecular imaging probes.

Authors:  Xin Lin; Jin Xie; Xiaoyuan Chen
Journal:  Amino Acids       Date:  2010-03-17       Impact factor: 3.520

Review 6.  Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2010-05-27       Impact factor: 3.402

7.  CoCl2 increases the expression of hypoxic markers HIF-1α, VEGF and CXCR4 in breast cancer MCF-7 cells.

Authors:  Qing Li; Rong Ma; Mei Zhang
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

Review 8.  Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.

Authors:  Chelsea C Estrada; Alejandro Maldonado; Sandeep K Mallipattu
Journal:  J Am Soc Nephrol       Date:  2019-01-14       Impact factor: 10.121

9.  In vivo characterization of 68Ga-NOTA-VEGF 121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models.

Authors:  Choong Mo Kang; Sung-Min Kim; Hyun-Jung Koo; Min Su Yim; Kyung-Han Lee; Eun Kyoung Ryu; Yearn Seong Choe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-25       Impact factor: 9.236

10.  Targeting prion-like protein doppel selectively suppresses tumor angiogenesis.

Authors:  Taslim A Al-Hilal; Seung Woo Chung; Jeong Uk Choi; Farzana Alam; Jooho Park; Seong Who Kim; Sang Yoon Kim; Fakhrul Ahsan; In-San Kim; Youngro Byun
Journal:  J Clin Invest       Date:  2016-03-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.